ReviewEvolution, medicine, and public health2014
Limits to compensatory adaptation and the persistence of antibiotic resistance in pathogenic bacteria.
Review in Evolution, medicine, and public health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 62 citations in OpenAlex.
- The Convergence of Antimicrobial Resistance and Virulence inMicroorganisms · 2026Review
- Antibiotic resistance increases evolvability and maximizes opportunities across fitness landscapes.Frontiers in microbiology · 2026Article
- Deciphering and steering population-level response under spatial drug heterogeneity on microhabitat structures.bioRxiv : the preprint server for biology · 2025Article
- Heterogeneous Phenotypic Responses of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Regulatory fine-tuning of mcr-1 increases bacterial fitness and stabilises antibiotic resistance in agricultural settings.The ISME journal · 2023Article
- The balance between antibiotic resistance and fitness/virulence inFrontiers in microbiology · 2023Review
- Article
- TheFrontiers in microbiology · 2021Article
- Article
- Exploiting evolutionary trade-offs for posttreatment management of drug-resistant populations.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.Antimicrobial agents and chemotherapy · 2020Article
- Steering Phages to Combat Bacterial Pathogens.Trends in microbiology · 2020Review
- Insights Into the Resistome of Bovine Clinical Mastitis Microbiome, a Key Factor in Disease Complication.Frontiers in microbiology · 2020Article
- Projecting the impact of variable MDR-TB transmission efficiency on long-term epidemic trends in South Africa and Vietnam.Scientific reports · 2019Article
- Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Article
- Characterization of the Microbial Resistome in Conventional and "Raised Without Antibiotics" Beef and Dairy Production Systems.Frontiers in microbiology · 2019Article
- Have compensatory mutations facilitated the current epidemic of multidrug-resistant tuberculosis?Emerging microbes & infections · 2018Article
- The emergence, maintenance, and demise of diversity in a spatially variable antibiotic regime.Evolution letters · 2018Article
- Antibiotic Persistence as a Metabolic Adaptation: Stress, Metabolism, the Host, and New Directions.Pharmaceuticals (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Antibiotic resistance carries a fitness cost that could potentially limit the spread of resistance in bacterial pathogens. In spite of this cost, a large number of experimental evolution studies have found that resistance is stably maintained in the absence of antibiotics as a result of compensatory evolution. Clinical studies, on the other hand, have found that resistance in pathogen populations usually declines after antibiotic use is stopped, suggesting that compensatory adaptation is not effective in vivo. In this article, we argue that this disagreement arises because there are limits to compensatory adaptation in nature that are not captured by the design of current laboratory selection experiments. First, clinical treatment fails to eradicate antibiotic-sensitive strains, and competition between sensitive and resistant strains leads to the rapid loss of resistance following treatment. Second, laboratory studies overestimate the efficacy of compensatory adaptation in nature by failing to capture costs associated with compensatory mutations. Taken together, these ideas can potentially reconcile evolutionary theory with the clinical dynamics of antibiotic resistance and guide the development of strategies for containing resistance in clinical pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.